Peel Hunt reissued their buy rating on shares of Circassia Pharmaceuticals (LON:CIR) in a report issued on Monday morning, ThisIsMoney.Co.Uk reports.
Separately, Numis Securities reissued a buy rating and issued a GBX 110 ($1.44) price target on shares of Circassia Pharmaceuticals in a report on Wednesday, May 1st.
Shares of Circassia Pharmaceuticals stock opened at GBX 18.40 ($0.24) on Monday. Circassia Pharmaceuticals has a fifty-two week low of GBX 13.25 ($0.17) and a fifty-two week high of GBX 82.70 ($1.08). The firm has a fifty day moving average price of GBX 18.99 and a two-hundred day moving average price of GBX 26.81. The company has a market cap of $69.03 million and a PE ratio of -0.54.
Circassia Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of respiratory diseases. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; and Tudorza for the treatment of chronic obstructive pulmonary disease (COPD).
Recommended Story: What are the reasons investors use put options?
Receive News & Ratings for Circassia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.